Mark E. Stearns
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mark E. Stearns has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Youji Hu
Department of Pathology, Drexel University College of Medicine, 15th and Vine Streets, MS435 NCB1, Philadelphia, PA 19102-1192, USA
4 shared publicationsMin Wang
3 shared publications- Fernando U. Garcia
Department of Pathology and Laboratory Medicine, Drexel University, College of Medicine, Philadelphia, Pennsylvania
2 shared publications M Wang
11Department of Pathology and Laboratory Medicine, Drexel University College of Medicine, Mail Stop 435, 15th and Vine Sts, Philadelphia, PA 19102-1192, USA
2 shared publicationsMichael D. Amatangelo
Drexel University
2 shared publicationsS.M. Goodyear
Molecular Pathobiology Program, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102-1192, USA
2 shared publications
Latest Publications
- 18 October 2011
- Published by Springer Nature
- p. 13-69
Reactivation of Epithelial-Mesenchymal Transition in Invasive and Metastatic Cancer
- 18 October 2011
- Published by Springer Nature
- p. 13-69
Reactivation of Epithelial-Mesenchymal Transition in Invasive and Metastatic Cancer
- Open Access
- 1 June 2011
- Published by Elsevier in Translational Oncology
- Vol. 4 (3) , 147-156
Synergistic Effects of the Green Tea Extract Epigallocatechin-3-gallate and Taxane in Eradication of Malignant Human Prostate Tumors
- 1 June 2011
- Published by Elsevier in Translational Oncology
- Vol. 4 (3) , 147-156
Open AccessSynergistic Effects of the Green Tea Extract Epigallocatechin-3-gallate and Taxane in Eradication of Malignant Human Prostate Tumors
- 1 December 2010
- Published by Elsevier in The American Journal of Pathology
- Vol. 177 (6) , 3169-3179
Combination Therapy with Epigallocatechin-3-Gallate and Doxorubicin in Human Prostate Tumor Modeling Studies
- 1 December 2010
- Published by Elsevier in The American Journal of Pathology
- Vol. 177 (6) , 3169-3179
Combination Therapy with Epigallocatechin-3-Gallate and Doxorubicin in Human Prostate Tumor Modeling Studies
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
847 Establishment and Characterization of a Novel Gallbladder Cell Line to Study Gallbladder Cancer and Gallstones
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
847 Establishment and Characterization of a Novel Gallbladder Cell Line to Study Gallbladder Cancer and Gallstones
- 19 March 2009
- Published by Wiley in The Prostate
- Vol. 69 (9) , 982-990
Role of the VEGFR3/VEGFD receptor axis in TGFβ1 activation of primary prostate cell lines
BACKGROUND: Reports indicate that vascular endothelial growth factor receptor type 3 (VEGFR3) regulates cellular functions such as invasion, proliferation, and chemo‐resistance. However, the exact function of the VEGFR3 signaling axis in prostate epithelial cells is poorly characterized.METHODS: The goal of this study was to evaluate whether TGFβ1 in combination with VEGFD can promote pre‐malignant invasive activities of intermediate basal cells (IBC‐10a) isolated from human prostate cancer (Gleason score 6).RESULTS: hTERT immortalized IBC‐10a cells normally grew as confluent “cobblestoned” monolayers, but treatment with TGFβ1 (10 ng/ml for 2–6 hr) dissociated the cell–cell junctions and induced VEGFR3 translocation to the cell surface. This event was not inhibited by 10 µM cycloheximide or puromycin, indicating transcription and protein synthesis were not required. We further discovered that TGFβ1 in combination with VEGFD induced a significant increase in the invasive activity of IBC‐10a cells (>26% and 53% after 24 and 48 hr, respectively) in modified Boyden Chamber assays. TGFβRII receptor antibodies specifically blocked TGFβ1 induction of VEGFR3 translocation to the cell surface and blocked VEGFD‐induced invasion. Zymograms revealed that TGFβ1 (and not VEGFR3) stimulated the secretion of MMP‐2 and MMP‐9, presumably to promote cell invasion. The cell invasion assays confirmed that antibodies specific for TGFβII receptor, MMP‐2 and MMP‐9 and VEGFR3, independently blocked TGFβ1‐induced invasion.CONCLUSIONS: For the first time, we have demonstrated the mechanism by which TGFβ1 stimulates VEGFD/VEGFR3 receptor axis activation leading to increased cell migration and invasion by primary intermediate basal cell cultures. Prostate 69: 982–990, 2009.
- 19 March 2009
- Published by Wiley in The Prostate
- Vol. 69 (9) , 982-990
Role of the VEGFR3/VEGFD receptor axis in TGFβ1 activation of primary prostate cell lines
BACKGROUND: Reports indicate that vascular endothelial growth factor receptor type 3 (VEGFR3) regulates cellular functions such as invasion, proliferation, and chemo‐resistance. However, the exact function of the VEGFR3 signaling axis in prostate epithelial cells is poorly characterized.METHODS: The goal of this study was to evaluate whether TGFβ1 in combination with VEGFD can promote pre‐malignant invasive activities of intermediate basal cells (IBC‐10a) isolated from human prostate cancer (Gleason score 6).RESULTS: hTERT immortalized IBC‐10a cells normally grew as confluent “cobblestoned” monolayers, but treatment with TGFβ1 (10 ng/ml for 2–6 hr) dissociated the cell–cell junctions and induced VEGFR3 translocation to the cell surface. This event was not inhibited by 10 µM cycloheximide or puromycin, indicating transcription and protein synthesis were not required. We further discovered that TGFβ1 in combination with VEGFD induced a significant increase in the invasive activity of IBC‐10a cells (>26% and 53% after 24 and 48 hr, respectively) in modified Boyden Chamber assays. TGFβRII receptor antibodies specifically blocked TGFβ1 induction of VEGFR3 translocation to the cell surface and blocked VEGFD‐induced invasion. Zymograms revealed that TGFβ1 (and not VEGFR3) stimulated the secretion of MMP‐2 and MMP‐9, presumably to promote cell invasion. The cell invasion assays confirmed that antibodies specific for TGFβII receptor, MMP‐2 and MMP‐9 and VEGFR3, independently blocked TGFβ1‐induced invasion.CONCLUSIONS: For the first time, we have demonstrated the mechanism by which TGFβ1 stimulates VEGFD/VEGFR3 receptor axis activation leading to increased cell migration and invasion by primary intermediate basal cell cultures. Prostate 69: 982–990, 2009.
- 13 January 2009
- Published by Wiley in The Prostate
- Vol. 69 (7) , 689-698
Dysplasia of human prostate CD133hi sub‐population in NOD‐SCIDS is blocked by c‐myc anti‐sense
BACKGROUND: The CD133hi sub‐population of prostate epithelial cells has been demonstrated to possess tumor‐initiating capacity consistent with that of the cancer stem cell theory. However, the involvement of oncogenes such as c‐myc has not been fully elucidated in the CD133hi sub‐population.METHODS: We have isolated primary prostate cell strains (IBC‐10a) and immortalized them by transfection with hTERT. The in vitro and in vivo tumorigenic capacity of isolated CD133hi and CD133lo cells was evaluated with respect to c‐myc expression using specific sense and anti‐sense oligonucleotides.RESULTS: Freshly immortalized cells consisted of hi/CD24hi sub‐population (SP). “Prostaspheres” generated from single CD133hi cells in the presence of EGF consisted of ∼10% CD133hi SPs in 12–21 day cultures. A single Prostasphere generated from single CD133hi cells (6–10 cell stage at day 6 injected i.t) produced dysplastic lesions in NOD‐SCID mice (n = 4/5). Treatment of Prostaspheres from CD133hi SPs in vitro with c‐myc or cyclin D1 anti‐sense oligonucleotides totally blocked colony forming ability and growth. Furthermore, treatment of fully formed, 6‐day Prostaspheres for 48 hr with c‐myc anti‐sense significantly reduced c‐myc expression and their ability to generate lesions in NOD‐SCIDs (n = 10 Prostaspheres injected i.t./mouse).CONCLUSIONS: These data demonstrate for the first time that a single CD133hi cell is competent to generate Prostaspheres in vitro and that CD133hi Prostaspheres require c‐myc to grow and form dysplastic lesions in vivo. Prostate 69: 689–698, 2009.
- 13 January 2009
- Published by Wiley in The Prostate
- Vol. 69 (7) , 689-698
Dysplasia of human prostate CD133hi sub‐population in NOD‐SCIDS is blocked by c‐myc anti‐sense
BACKGROUND: The CD133hi sub‐population of prostate epithelial cells has been demonstrated to possess tumor‐initiating capacity consistent with that of the cancer stem cell theory. However, the involvement of oncogenes such as c‐myc has not been fully elucidated in the CD133hi sub‐population.METHODS: We have isolated primary prostate cell strains (IBC‐10a) and immortalized them by transfection with hTERT. The in vitro and in vivo tumorigenic capacity of isolated CD133hi and CD133lo cells was evaluated with respect to c‐myc expression using specific sense and anti‐sense oligonucleotides.RESULTS: Freshly immortalized cells consisted of hi/CD24hi sub‐population (SP). “Prostaspheres” generated from single CD133hi cells in the presence of EGF consisted of ∼10% CD133hi SPs in 12–21 day cultures. A single Prostasphere generated from single CD133hi cells (6–10 cell stage at day 6 injected i.t) produced dysplastic lesions in NOD‐SCID mice (n = 4/5). Treatment of Prostaspheres from CD133hi SPs in vitro with c‐myc or cyclin D1 anti‐sense oligonucleotides totally blocked colony forming ability and growth. Furthermore, treatment of fully formed, 6‐day Prostaspheres for 48 hr with c‐myc anti‐sense significantly reduced c‐myc expression and their ability to generate lesions in NOD‐SCIDs (n = 10 Prostaspheres injected i.t./mouse).CONCLUSIONS: These data demonstrate for the first time that a single CD133hi cell is competent to generate Prostaspheres in vitro and that CD133hi Prostaspheres require c‐myc to grow and form dysplastic lesions in vivo. Prostate 69: 689–698, 2009.
- Open Access
- 12 January 2009
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 28 (1) , 6
RPS2: a novel therapeutic target in prostate cancer
Background: A number of studies have previously shown that the over expression of different ribosomal proteins might play an important role in cancer (i.e. S3a, L10, L16). We have previously reported that RPS2, a 33 Kda ribosomal protein was over expressed in malignant prostate cancer cell lines and in archived tumor specimens. Thus, RPS2 or other aberrantly over-expressed ribosomal proteins might promote cancer and be excellent therapeutic targets for treatment of the disease. Methods: Western blotting and RT-PCR have been used to measure and compare the levels of expression of RPS2 in a variety of malignant prostate cancer cell lines, plus normal and benign cells lines. We have developed a 'ribozyme-like' DNAZYM-1P '10–23' motif oligonucleotide and examined whether it targets RPS2 in different cell lines by RT-PCR and Western blots. Growth and apoptosis assays were carried out to measure whether DNAZYM-1P 'knock-down' of RPS2 influenced cell proliferation or survival. We have also developed a SCID mouse tumor model with PC-3ML cells to determine whether DNAZYM-1P targeting of RPS2 compromised tumor growth and mouse survival rates in vivo. Results: Western blots showed that PC-3ML, LNCaP, CPTX-1532, and pBABE-cmyc stably transfected IBC-10a cells all over-expressed RPS2, whereas IBC-10a parent, NPTX-1532, and BPH-1 cells or mouse NIH-3T3 cells expressed barely detectable levels of RPS2. RT-PCR assays showed that DNAZYM-1P, which targeted RPS2, 'knocked-down' RPS2 expression in the malignant cells (i.e. PC-3ML cells) in vitro. The DNAZYM-1P also inhibited cell growth and induced apoptosis in the malignant prostate cells, but had little effect on the normal IBC-10a or NPTX-1532 cell lines. Finally, SCID mouse tumor modeling studies showed that DNAZYM-1P blocked tumor growth and metastasis by PC-3ML cells and eventually eradicated tumors following localized or systemic i.v. delivery. Mouse survival studies revealed that there was a dosage dependent increase in disease free survival rates in mice treated systemically with DNAZYM-1P (i.e. mouse survival increased from 0% to 100%). Conclusion: In sum, we have shown for the first time that therapeutic targeting of RPS2 is an excellent approach for the eradication of prostate cancer in preclinical tumor modeling studies.
- 12 January 2009
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 28 (1) , 6
Open AccessRPS2: a novel therapeutic target in prostate cancer
Background: A number of studies have previously shown that the over expression of different ribosomal proteins might play an important role in cancer (i.e. S3a, L10, L16). We have previously reported that RPS2, a 33 Kda ribosomal protein was over expressed in malignant prostate cancer cell lines and in archived tumor specimens. Thus, RPS2 or other aberrantly over-expressed ribosomal proteins might promote cancer and be excellent therapeutic targets for treatment of the disease. Methods: Western blotting and RT-PCR have been used to measure and compare the levels of expression of RPS2 in a variety of malignant prostate cancer cell lines, plus normal and benign cells lines. We have developed a 'ribozyme-like' DNAZYM-1P '10–23' motif oligonucleotide and examined whether it targets RPS2 in different cell lines by RT-PCR and Western blots. Growth and apoptosis assays were carried out to measure whether DNAZYM-1P 'knock-down' of RPS2 influenced cell proliferation or survival. We have also developed a SCID mouse tumor model with PC-3ML cells to determine whether DNAZYM-1P targeting of RPS2 compromised tumor growth and mouse survival rates in vivo. Results: Western blots showed that PC-3ML, LNCaP, CPTX-1532, and pBABE-cmyc stably transfected IBC-10a cells all over-expressed RPS2, whereas IBC-10a parent, NPTX-1532, and BPH-1 cells or mouse NIH-3T3 cells expressed barely detectable levels of RPS2. RT-PCR assays showed that DNAZYM-1P, which targeted RPS2, 'knocked-down' RPS2 expression in the malignant cells (i.e. PC-3ML cells) in vitro. The DNAZYM-1P also inhibited cell growth and induced apoptosis in the malignant prostate cells, but had little effect on the normal IBC-10a or NPTX-1532 cell lines. Finally, SCID mouse tumor modeling studies showed that DNAZYM-1P blocked tumor growth and metastasis by PC-3ML cells and eventually eradicated tumors following localized or systemic i.v. delivery. Mouse survival studies revealed that there was a dosage dependent increase in disease free survival rates in mice treated systemically with DNAZYM-1P (i.e. mouse survival increased from 0% to 100%). Conclusion: In sum, we have shown for the first time that therapeutic targeting of RPS2 is an excellent approach for the eradication of prostate cancer in preclinical tumor modeling studies.
- Open Access
- 1 July 2004
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 2 (7) , 403-416
Interleukin-10 Induced Activating Transcription Factor 3 Transcriptional Suppression of Matrix Metalloproteinase-2 Gene Expression in Human Prostate CPTX-1532 Cells
Aberrant expression of the 72-kDa type IV collagenase [matrix metalloproteinase (MMP)-2] is implicated in the invasion and angiogenesis process of malignant tumors. We investigated the effects of interleukin (IL)-10 on MMP-2 expression in CPTX-1532 human prostate tumor cells. Our results demonstrate that IL-10 significantly inhibited MMP-2 transcription and protein expression induced by a phorbol ester, phorbol 12-myristate 13-acetate. The inhibitory effects of IL-10 on MMP-2 expression correlated with the suppression of MMP-2 promoter activity. To determine the mechanism of IL-10 action, we examined IL-10–dependent promoter activity with luciferase constructs from a 2-kbp promoter region of the human MMP-2 gene. We functionally characterized the promoter fragments by transient transfection experiments with CPTX-1532 cells. The experiments revealed that a cAMP responsive element binding protein (CREB) consensus domain was identified upstream of the 5′ transcriptional start site, which was highly responsive to IL-10–dependent down-regulation of promoter luciferase activity. Electrophoretic mobility shift assays combined with antibody “supershift assays” confirmed the data from the luciferase assays. Immunoblot assays of activating transcription factor (ATF) 3 immunoprecipitates with tyrosine specific antibodies revealed that IL-10 stimulated tyrosine phosphorylation of ATF3 to activate binding to the CREB domain and suppress MMP-2 expression. Studies with stable, IL-10 transfected CPTX-1532 subclones further showed that IL-10 failed to suppress MMP-2 expression in ATF3-deficient CPTX-1532 cells, where the ATF3 mRNA was destroyed with a DNAzyme oligonucleotide targeting the 5′ region of the mRNA. Finally, reconstitution of ATF3 successfully restored the inhibitory effects of IL-10 on MMP-2 gene expression. Taken together, these data demonstrate the critical role of tyrosine phosphorylated ATF3 and the CREB consensus domain in IL-10 suppression of MMP-2 gene expression in primary human prostate tumor cells.
- 1 July 2004
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 2 (7) , 403-416
Open AccessInterleukin-10 Induced Activating Transcription Factor 3 Transcriptional Suppression of Matrix Metalloproteinase-2 Gene Expression in Human Prostate CPTX-1532 Cells
Aberrant expression of the 72-kDa type IV collagenase [matrix metalloproteinase (MMP)-2] is implicated in the invasion and angiogenesis process of malignant tumors. We investigated the effects of interleukin (IL)-10 on MMP-2 expression in CPTX-1532 human prostate tumor cells. Our results demonstrate that IL-10 significantly inhibited MMP-2 transcription and protein expression induced by a phorbol ester, phorbol 12-myristate 13-acetate. The inhibitory effects of IL-10 on MMP-2 expression correlated with the suppression of MMP-2 promoter activity. To determine the mechanism of IL-10 action, we examined IL-10–dependent promoter activity with luciferase constructs from a 2-kbp promoter region of the human MMP-2 gene. We functionally characterized the promoter fragments by transient transfection experiments with CPTX-1532 cells. The experiments revealed that a cAMP responsive element binding protein (CREB) consensus domain was identified upstream of the 5′ transcriptional start site, which was highly responsive to IL-10–dependent down-regulation of promoter luciferase activity. Electrophoretic mobility shift assays combined with antibody “supershift assays” confirmed the data from the luciferase assays. Immunoblot assays of activating transcription factor (ATF) 3 immunoprecipitates with tyrosine specific antibodies revealed that IL-10 stimulated tyrosine phosphorylation of ATF3 to activate binding to the CREB domain and suppress MMP-2 expression. Studies with stable, IL-10 transfected CPTX-1532 subclones further showed that IL-10 failed to suppress MMP-2 expression in ATF3-deficient CPTX-1532 cells, where the ATF3 mRNA was destroyed with a DNAzyme oligonucleotide targeting the 5′ region of the mRNA. Finally, reconstitution of ATF3 successfully restored the inhibitory effects of IL-10 on MMP-2 gene expression. Taken together, these data demonstrate the critical role of tyrosine phosphorylated ATF3 and the CREB consensus domain in IL-10 suppression of MMP-2 gene expression in primary human prostate tumor cells.
- Open Access
- 28 October 2003
- Published by Springer Nature in British Journal of Cancer
- Vol. 89 (9) , 1812-1813
Reply: TIMP-1 enhancer sequence – real or bacterial?
- 28 October 2003
- Published by Springer Nature in British Journal of Cancer
- Vol. 89 (9) , 1812-1813
Open AccessReply: TIMP-1 enhancer sequence – real or bacterial?
- 1 July 2003
- Vol. 1 (9) , 631-42
Interleukin-10 activation of the interleukin-10E1 pathway and tissue inhibitor of metalloproteinase-1 expression is enhanced by proteasome inhibitors in primary prostate tumor lines.
The interleukin-10 (IL-10) activation of Janus kinase (JAK) family members (JAK1/TYK2) and IL-10E1 is subsequently inactivated by approximately 3-4 h in primary prostate tumor lines. We examined the effect of proteasome inhibition on IL-10 activation of the IL-10E1 pathway following stimulation of HPCA-10a cells. Treatment of HPCA-10a cells with the proteasome inhibitor, N-acetyl-L-leucinyl-L-leucinyl-norleucinal (LLnL), led to stable tyrosine phosphorylation of the IL-10 receptor and IL-10E1 following stimulation. Further investigation showed that these stable phosphorylation events were the result of prolonged activation of JAK1 and TYK2 plus IL-10E1. IL-10E1 signaling normally induced the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) and LLnL treatment of the HPCA-10a and HPCA-10c cells significantly enhanced IL-10 induction of TIMP-1 levels to block tumor cell invasion in modified Boyden chamber invasion assays. These observations were confirmed using pharmacologic inhibitors by Western blot and ELISAs. In the presence of LLnL, stable phosphorylation of IL-10E1 and induction of TIMP-1 was abrogated if the tyrosine kinase inhibitor, staurosporine, was added. The effect of staurosporine on IL-10E1 phosphorylation and TIMP-1 could be overcome if the phosphatase inhibitor, vanadate, was also added, suggesting that phosphorylated IL-10E1 could be stabilized by phosphatase, but not by proteasome inhibition. These observations are consistent with the hypothesis that proteasome-mediated protein degradation can modulate the activity of the IL-10E1 pathway and TIMP-1 induction by regulating the deactivation of JAK1/TYK2.
- 1 July 2003
- Vol. 1 (9) , 631-42
Interleukin-10 activation of the interleukin-10E1 pathway and tissue inhibitor of metalloproteinase-1 expression is enhanced by proteasome inhibitors in primary prostate tumor lines.
The interleukin-10 (IL-10) activation of Janus kinase (JAK) family members (JAK1/TYK2) and IL-10E1 is subsequently inactivated by approximately 3-4 h in primary prostate tumor lines. We examined the effect of proteasome inhibition on IL-10 activation of the IL-10E1 pathway following stimulation of HPCA-10a cells. Treatment of HPCA-10a cells with the proteasome inhibitor, N-acetyl-L-leucinyl-L-leucinyl-norleucinal (LLnL), led to stable tyrosine phosphorylation of the IL-10 receptor and IL-10E1 following stimulation. Further investigation showed that these stable phosphorylation events were the result of prolonged activation of JAK1 and TYK2 plus IL-10E1. IL-10E1 signaling normally induced the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) and LLnL treatment of the HPCA-10a and HPCA-10c cells significantly enhanced IL-10 induction of TIMP-1 levels to block tumor cell invasion in modified Boyden chamber invasion assays. These observations were confirmed using pharmacologic inhibitors by Western blot and ELISAs. In the presence of LLnL, stable phosphorylation of IL-10E1 and induction of TIMP-1 was abrogated if the tyrosine kinase inhibitor, staurosporine, was added. The effect of staurosporine on IL-10E1 phosphorylation and TIMP-1 could be overcome if the phosphatase inhibitor, vanadate, was also added, suggesting that phosphorylated IL-10E1 could be stabilized by phosphatase, but not by proteasome inhibition. These observations are consistent with the hypothesis that proteasome-mediated protein degradation can modulate the activity of the IL-10E1 pathway and TIMP-1 induction by regulating the deactivation of JAK1/TYK2.